Frazier Financial Advisors, LLC Catalyst Pharmaceuticals, Inc. Transaction History
Frazier Financial Advisors, LLC
- $129 Billion
- Q3 2024
A detailed history of Frazier Financial Advisors, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Frazier Financial Advisors, LLC holds 82 shares of CPRX stock, worth $1,761. This represents 0.0% of its overall portfolio holdings.
Number of Shares
82Holding current value
$1,761% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CPRX
# of Institutions
327Shares Held
94.6MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$402 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.04MShares$173 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$134 Million2.3% of portfolio
-
State Street Corp Boston, MA5.69MShares$122 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$64.8 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.21B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...